Issue Date: February 12, 2007
GSK Signs For Two Late-Stage Compounds
GlaxoSmithKline has agreed to codevelop XenoPort's XP13512, a prodrug of the pain treatment gabapentin that improves gabapentin's bioavailability. XP13512 is in Phase III trials for restless legs syndrome. XenoPort will get an up-front payment of $78 million and could reap milestone and other payments of up to $580 million. Separately, GSK will commercialize Fabre-Kramer Pharmaceuticals' gepirone ER, a 5HT1a agonist expected to be submitted to FDA this quarter as a treatment for major depressive disorder. Financial terms weren't disclosed.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society